Warwick N R, Graham G G, Torda T A
Department of Anaesthetics, Westmead Hospital, School of Physiology and Pharmacology, University of New South Wales, Australia.
Clin Pharmacol Ther. 1995 Apr;57(4):390-7. doi: 10.1016/0009-9236(95)90207-4.
To examine the ability to determine clinically important pharmacokinetic and pharmacodynamic parameters of atracurium by the analysis of the time course of effect without the use of plasma concentration data.
Neuromuscular transmission was monitored with train-of-four stimulation and electromyographic quantitation of the first (T1) and fourth (T4) responses in eight anesthetized patients undergoing elective surgery. The time course of onset and recovery of neuromuscular blockade by three successive bolus doses of atracurium was recorded. Equations describing the theoretic time course of concentrations in the effect compartment and the dose-response relationship were fitted simultaneously to these data; the parameters of these equations derived from the fit of two doses were used to predict the response to a third dose. Fitting the equations to all three doses was also performed to assess the accuracy of predictions for atracurium.
From the depression of the first twitch after three consecutive doses in eight patients, the half-lives of uptake into and elimination from the effect compartment were 2.1 +/- 0.2 minutes (mean +/- SEM) and 25.8 +/- 2.3 minutes (n = 8). The doses producing 50% and 95% depression of the first twitch (ED50 and ED95) were 168 +/- 15 and 280 +/- 25 micrograms/kg, respectively, with a Hill coefficient of 6.1 +/- 0.5. The half-life of elimination estimated from the fourth twitch was similar to that from the first twitch.
The analysis of high-resolution effect data is capable of giving pharmacokinetic and pharmacodynamic parameters with clinically acceptable accuracy within a short sampling time, without resorting to laboratory analysis. This method is specific for active drug and would be of value for individualization of administration for short-term treatment.
在不使用血浆浓度数据的情况下,通过分析效应的时间进程来检验确定阿曲库铵临床重要药代动力学和药效学参数的能力。
对八名接受择期手术的麻醉患者,采用四个成串刺激和对第一个(T1)及第四个(T4)反应的肌电图定量监测神经肌肉传递。记录三次连续推注剂量阿曲库铵后神经肌肉阻滞起效和恢复的时间进程。将描述效应室浓度理论时间进程和剂量 - 反应关系的方程同时拟合这些数据;由两剂拟合得到的这些方程的参数用于预测对第三剂的反应。还对所有三剂进行方程拟合以评估阿曲库铵预测的准确性。
根据八名患者连续三次给药后第一个肌颤搐的抑制情况,效应室摄取半衰期和消除半衰期分别为2.1±0.2分钟(均值±标准误)和25.8±2.3分钟(n = 8)。产生第一个肌颤搐50%和95%抑制的剂量(ED50和ED95)分别为168±15和280±25微克/千克,希尔系数为6.1±0.5。根据第四个肌颤搐估计的消除半衰期与根据第一个肌颤搐估计的相似。
对高分辨率效应数据的分析能够在短采样时间内给出临床可接受准确性的药代动力学和药效学参数,而无需进行实验室分析。该方法针对活性药物具有特异性,对短期治疗给药个体化有价值。